# US 2010/0136659 A1 · Infectious cDNA Clone of North American Porcine Reproductive and Respiratory Syndrome (PPRS) Virus and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136659 A1
- Document ID: US20100136659A1
- Status: Published application
- Kind: A1
- Application number: 12/607,358
- Filed: 2009-10-28
- Published: 2010-06-03
- Earliest claimed: 1998-12-22
- Assignees: Pfizer Inc.
- Inventors: Jay Gregory Calvert; Michael G. Sheppard; Siao-Kun W. Welch; Raymond R. R. Rowland; Dal-Young Kim
- Web page: https://patentgrep.com/patent/US20100136659A1

## CPC

- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- A61K 2039/525: {Virus}
- A61K 2039/53: {DNA (RNA) vaccination}
- C12N 2770/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/10043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus. These viral vectors and transfected host cell lines are useful in providing peptides to compensate for mutated peptide coding sequences of DNA sequences encoding genetically-modified North American PRRS viruses so that functional virions can be generated.

## Claims

### Claim 1

An isolated polynucleotide molecule comprising a DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus that is genetically modified such that when it infects a porcine animal it is unable to produce PRRS in the animal, wherein said DNA sequence is SEQ ID NO:1 or a sequence homologous thereto.

### Claim 2 (depends on 1)

An isolated polynucleotide molecule of claim 1, comprising a DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus that is genetically modified such that it comprises one or more detectable heterologous antigenic epitopes, wherein the DNA sequence encoding the infectious RNA molecule is the same as or homologous to the sequence SEQ ID NO:1 or a sequence homologous thereto except for that it comprises one or more further nucleotide sequences that each encode a detectable heterologous antigenic epitope.

### Claim 3 (depends on 2)

The isolated polynucleotide molecule of claim 2, wherein said nucleotide sequences that each encode a heterologous antigenic epitope are inserted between ORF 1b and ORF 2 within said DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus.

### Claim 4 (depends on 2)

The isolated polynucleotide molecule of claim 2, wherein said nucleotide sequences that each encode a heterologous antigenic epitope are inserted in ORF 1a or ORF 1b within said DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus.

### Claim 5 (depends on 4)

The isolated polynucleotide molecule of claim 4, wherein said nucleotide sequences that each encode a heterologous antigenic epitope are inserted in the nonstructural protein 2 coding region of ORF1a within said DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus.

### Claim 6 (depends on 5)

The isolated polynucleotide molecule of claim 5, wherein said nucleotide sequences that each encode a heterologous antigenic epitope are inserted in the hypervariable region in the nonstructural protein 2 coding region of ORF1a within said DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus.

### Claim 7 (depends on 6)

The isolated polynucleotide molecule of claim 6, wherein said nucleotide sequences that each encode a heterologous antigenic epitope are inserted in at position 3219 in the hypervariable region in the nonstructural protein 2 coding region of ORF1a within said DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus.

### Claim 8 (depends on 2)

The isolated polynucleotide molecule of claim 2, wherein transcription of said polynucleotide molecule results in formation of a genomic RNA and subsequent formation of subgenomic RNA molecules, and wherein at least one heterologous antigenic epitope is translated directly from the genomic RNA molecule.

### Claim 9 (depends on 2)

The isolated polynucleotide molecule of claim 2, wherein transcription of said polynucleotide molecule results in formation of a genomic RNA and subsequent formation of subgenomic RNA molecules, and wherein at least one heterologous antigenic epitope is translated from a subgenomic RNA molecule.

### Claim 10 (depends on 8)

The isolated polynucleotide molecule of claim 8, wherein translation of said genomic or subgenomic RNA molecules results in formation of individual fusion proteins following translation, said proteins consisting essentially of a fusion between a PRRS virus protein and said heterologous antigenic epitope.

### Claim 11 (depends on 8)

The isolated polynucleotide molecule of claim 8, wherein translation of said genomic or subgenomic RNA molecules results in formation of a protein consisting essentially of the heterologous antigenic epitope.

### Claim 12 (depends on 9)

The isolated polynucleotide molecule of claim 9, wherein translation of said genomic or subgenomic RNA molecules results in formation of individual fusion proteins following translation, said proteins consisting essentially of a fusion between a PRRS virus protein and said heterologous antigenic epitope.

### Claim 13 (depends on 9)

The isolated polynucleotide molecule of claim 9, wherein translation of said genomic or subgenomic RNA molecules results in formation of a protein consisting essentially of the heterologous antigenic epitope.

### Claim 14

A plasmid capable of directly transfecting a suitable host cell and expressing a Nidovirales virus from the suitable host cell so transfected, which plasmid comprises a) a DNA sequence encoding an infectious RNA molecule encoding the Nidovirales virus, and b) a promoter capable of transcribing said infectious RNA molecule in said suitable host cell.

### Claim 15 (depends on 14)

A plasmid of claim 14, where said DNA sequence encodes an infectious RNA molecule encoding a North American PRRS virus that is genetically modified such that when it infects a porcine animal it is unable to produce PRRS in the animal, wherein said DNA sequence is SEQ ID NO:1 or a sequence homologous thereto.

### Claim 16 (depends on 15)

A plasmid of claim 15, where said DNA sequence encodes an infectious RNA molecule encoding a North American PRRS virus that is genetically modified such that it comprises one or more detectable heterologous antigenic epitopes, wherein the DNA sequence encoding the infectious RNA molecule is the same as or homologous to the sequence SEQ ID NO:1 or a sequence homologous thereto except for that it comprises one or more further nucleotide sequences that each encode a detectable heterologous antigenic epitope.

### Claim 17

A transfected host cell comprising a DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus that is genetically modified such that when it infects a porcine animal it is unable to produce PRRS in the animal, wherein said DNA sequence is SEQ ID NO:1 or a sequence homologous thereto, which transfected host cell is capable of expressing the encoded genetically modified North American PRRS virus.

### Claim 18 (depends on 17)

A transfected host cell, of claim 17, comprising a DNA sequence encoding an infectious RNA molecule encoding a North American PRRS virus that is genetically modified such that when it infects a porcine animal it is unable to produce PRRS in the animal, wherein said DNA sequence is SEQ ID NO:1 or a sequence homologous thereto, except for that it contains one or more mutations that genetically disable the encoded PRRS virus in its ability to produce PRRS, which transfected host cell is capable of expressing the encoded genetically modified North American PRRS virus.
